| |
| |
| Exchange: |
N/A |
| Security
Type: |
Common |
| Shares
Out: |
82,110,000 |
| Market
Cap: |
3.30(B) |
| Last
Volume: |
0 |
Avg
Vol: |
0 |
| 52
Week Range: |
$31.73 - $53.69 |
|
| Level
I Sector: |
Consumer Discretionary |
| Level
II Sector: |
Leisure |
| Level
III Sector: |
Restaurants |
|
Member Indexes:
|
| |
S&P COMPOSITE 1500 |
|
NASDAQ COMPOSITE |
| |
NASDAQ INDUSTRIAL |
|
S&P SMALLCAP 600 |
| |
NASDAQ NNM COMPOSITE |
|
Rankings:
|
|
| Insider 3 Months : - |
| Insider 6 Months : - |
| Insider 3/6 Months : - |
|
| Guru Rank Number : - |
| Guru Rank Value : - |
| Guru Occurances : - |
|
|
|
|
|
| |
|
Company Profile Ultragenyx Pharmaceutical is a biopharmaceutical company focused on the identification, acquisition, development, and commercialization of products for the treatment of genetic diseases. Co. has four commercially approved products, Crysvita® (burosumab) for the treatment of X-linked hypophosphatemia and tumor-induced osteomalacia, Mepsevii® (vestronidase alfa) for the treatment of mucopolysaccharidosis VII, or Sly Syndrome, Dojolvi® (triheptanoin) for the treatment of long-chain fatty acid oxidation disorders, and Evkeeza® (evinacumab) for the treatment of homozygous familial hypercholesterolemia.
|
|
|
D/I:
|
|
|
D
is for direct shares.
I is
for indirect shares.
D/I
refers to the Direct or Indirect
shares traded vs. held. |
|
|
|
Forms:
|
|
|
A
Form 4 is a form filed
by an insider to indicate a change
in ownership.
A Form
3 is a form filed by
an insider to indicate an
initial ownership of a security. |
|
|
|
3m +/-:
|
|
|
|
This
represents the company's 3 month
price change. The initial price
is based on the closing price
of the stock on the day the transaction
took place. Purchases & sales
are viewed as long & short
positions respectively.
|
|
|
|
Actions:
|
|
|
| B |
Buy |
| S |
Sell |
| OE |
Option
Exercised |
| A |
Acquired |
| D |
Disposed |
| AB |
Automatic
Buy |
| AS |
Automatic
Sell |
| IO |
Initial
Ownership |
|
|
|
|
Download:
|
|
|
Download only Transactions
Forms. (Default)
Download
only Summary Infomation.
Download
both Transactions and Summary Data
|
|
|
|
|
| |
| |
Summary (Direct Transactions Only)  |
3 Months |
6 Months |
12 Months |
24 Months |
| Total Shares Bought |
0 |
0 |
0 |
0 |
| Total Buy Value |
$0 |
$0 |
$0 |
$0 |
| Total People Bought |
0 |
0 |
0 |
0 |
| Total Buy Transactions |
0 |
0 |
0 |
0 |
| Total Shares Sold |
24,200 |
99,487 |
198,726 |
249,694 |
| Total Sell Value |
$1,216,805 |
$4,824,734 |
$8,206,765 |
$10,494,293 |
| Total People Sold |
3 |
8 |
9 |
12 |
| Total Sell Transactions |
4 |
12 |
20 |
35 |
| End Date |
2024-03-03 |
2023-12-01 |
2023-06-02 |
2022-06-02 |
|
| Filer's Name |
Relation Title |
Off-Dir-10% |
Tran. Date |
Form |
Action |
Price |
Mkt Value |
D/I |
Shares |
Holdings |
Rank
|
|
|
| 3m +/- |
|
|
Form |
  Kakkis Emil D |
President & CEO |
• • – |
2016-05-21 |
4 |
D |
$64.01 |
$68,619 |
D/D |
(1,072) |
516,447 |
|
- |
|
| Sharp Shalini |
CFO & Senior Vice President |
• – – |
2016-05-21 |
4 |
D |
$64.01 |
$26,500 |
D/D |
(414) |
41,387 |
|
- |
|
| Huizenga Theodore Alan |
Controller and PAO |
• – – |
2016-05-21 |
4 |
D |
$64.01 |
$10,626 |
D/D |
(166) |
4,334 |
|
- |
|
| Kassberg Thomas Richard |
CBO & Senior Vice President |
• – – |
2016-05-21 |
4 |
D |
$64.01 |
$26,500 |
D/D |
(414) |
69,790 |
|
- |
|
| Agarwal Sunil |
Chief Medical Officer |
• – – |
2016-05-21 |
4 |
D |
$64.01 |
$26,500 |
D/D |
(414) |
7,761 |
|
- |
|
| Agarwal Sunil |
Chief Medical Officer |
• – – |
2016-05-19 |
4 |
D |
$61.46 |
$24,092 |
D/D |
(392) |
8,175 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2016-05-16 |
4 |
AS |
$59.37 |
$1,199,095 |
D/D |
(20,000) |
517,519 |
|
- |
|
| Huang Dennis Karl |
SVP and Chief Tech Ops Officer |
• – – |
2016-05-05 |
4 |
D |
$62.45 |
$44,027 |
D/D |
(705) |
6,795 |
|
- |
|
| Agarwal Sunil |
Chief Medical Officer |
• – – |
2016-04-20 |
4 |
AS |
$70.53 |
$45,774 |
D/D |
(649) |
8,567 |
|
- |
|
| Agarwal Sunil |
Chief Medical Officer |
• – – |
2016-04-19 |
4 |
D |
$69.86 |
$27,385 |
D/D |
(392) |
9,216 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2016-04-15 |
4 |
AS |
$69.46 |
$1,406,554 |
D/D |
(20,000) |
537,519 |
|
- |
|
| Agarwal Sunil |
Chief Medical Officer |
• – – |
2016-03-22 |
4 |
AS |
$61.45 |
$39,943 |
D/D |
(650) |
9,608 |
|
- |
|
| Agarwal Sunil |
Chief Medical Officer |
• – – |
2016-03-19 |
4 |
D |
$56.32 |
$22,077 |
D/D |
(392) |
10,258 |
|
- |
|
| Agarwal Sunil |
Chief Medical Officer |
• – – |
2016-02-22 |
4 |
AS |
$63.48 |
$41,770 |
D/D |
(658) |
10,650 |
|
- |
|
| Agarwal Sunil |
Chief Medical Officer |
• – – |
2016-02-19 |
4 |
D |
$63.27 |
$24,296 |
D/D |
(384) |
11,308 |
|
- |
|
| Huizenga Theodore Alan |
Controller and PAO |
• – – |
2016-02-12 |
4 |
OE |
$21.00 |
$21,000 |
D/D |
1,000 |
4,500 |
|
- |
|
| Agarwal Sunil |
Chief Medical Officer |
• – – |
2016-01-20 |
4 |
AS |
$72.83 |
$42,606 |
D/D |
(585) |
12,190 |
|
- |
|
| Agarwal Sunil |
Chief Medical Officer |
• – – |
2016-01-19 |
4 |
D |
$71.52 |
$32,613 |
D/D |
(456) |
12,775 |
|
- |
|
| Huizenga Theodore Alan |
Controller and PAO |
• – – |
2016-01-14 |
4 |
OE |
$21.00 |
$21,000 |
D/D |
1,000 |
3,500 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2015-12-31 |
4 |
AS |
$112.91 |
$624,294 |
D/D |
(5,498) |
575,640 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2015-12-30 |
4 |
AS |
$113.30 |
$1,666,198 |
D/D |
(14,502) |
581,138 |
|
- |
|
| Aliski William |
|
– • – |
2015-12-29 |
5 |
GD |
$0.00 |
$0 |
D/D |
1,900 |
58,110 |
|
- |
|
| Agarwal Sunil |
Chief Medical Officer |
• – – |
2015-12-22 |
4 |
AS |
$114.81 |
$57,175 |
D/D |
(498) |
13,231 |
|
- |
|
| Agarwal Sunil |
Chief Medical Officer |
• – – |
2015-12-19 |
4 |
D |
$109.87 |
$59,769 |
D/D |
(544) |
13,729 |
|
- |
|
| Kakkis Emil D |
President & CEO |
• • – |
2015-12-18 |
5 |
GD |
$0.00 |
$0 |
D/D |
18,121 |
557,519 |
|
- |
|
628 Records found
|
|
Page 22 of 26 |
|
|
1.49 (3.86%) 
